Almirall Refines Board Committees and Advances Scrip Dividend Plan

Almirall ( (ES:ALM) ) has provided an update.

Almirall’s board, meeting after the 8 May 2026 shareholders’ meeting, confirmed a series of governance moves, including the re-election of Eva Abans Iglesias as chair of the Audit and Sustainability Committee and the re-election of Ugo Di Francesco to the Appointments and Remuneration Committee. The board also shifted responsibilities by adding Antonio Gallardo Torrededía to the Appointments and Remuneration Committee, moving him off the Audit and Sustainability Committee, and appointing Ivana Magovčević-Liebisch to both the Audit and Sustainability and Dermatology committees, signaling a focus on oversight and dermatology expertise.

The board further agreed to execute a previously approved share capital increase tied to a scrip dividend, allowing shareholders to receive new shares instead of a traditional cash payout. This move supports capital flexibility and may appeal to investors seeking equity participation, while the company has committed to provide additional details on the mechanics of the scrip dividend to the market.

The most recent analyst rating on (ES:ALM) stock is a Hold with a EUR14.00 price target. To see the full list of analyst forecasts on Almirall stock, see the ES:ALM Stock Forecast page.

More about Almirall

Almirall, S.A. is a pharmaceutical company focused on developing and commercializing medicines, with a particular emphasis on dermatology and related therapeutic areas. The company targets global healthcare markets by offering prescription treatments that address unmet medical needs in skin and other specialty conditions.

Average Trading Volume: 149,849

Technical Sentiment Signal: Buy

Current Market Cap: €2.57B

See more data about ALM stock on TipRanks’ Stock Analysis page.